Literature DB >> 31218404

CD39 downregulation in chronic intervillositis of unknown etiology.

Yuichiro Sato1, Kazunari Maekawa2, Murasaki Aman3, Atushi Yamashita2, Yuki Kodama4, Yohei Maki4, Hiroshi Sameshima4, Yujiro Asada2.   

Abstract

Chronic intervillositis of unknown etiology (CIUE) is a rare placental lesion associated with infiltration of mononuclear inflammatory cells into the intervillous space, poor perinatal outcomes (intrauterine fetal demise or fetal growth restriction), and high rates of recurrence. CD39 is the ectonucleotidase that protects tissues from inflammatory stress and cell injury, which is localized on the surface of villi in normal placentas; however, its expression and role in CIUE are unknown. The aims of this retrospective study were to determine the expression of CD39 in CIUE and its significance in pregnancy outcomes. We compared the number of CD68- and CD3-positive cells, CD39 expression, and complement 4d (C4d) and fibrin deposition in placental tissues from patients with CIUE (n = 22) and gestational age-matched controls (n = 20), and between CIUE pregnancies with poor and good outcomes. The numbers of CD68- or CD3-positive cells were significantly higher (P < 0.0001), whereas CD39 expression on the surface of villi and endothelial cells of the stem villi was significantly lower in the CIUE group than that in controls (45% vs. 95%, P < 0.0001 and 77% vs. 96%, P < 0.001, respectively). C4d and fibrin deposition were also significantly increased in CIUE compared with those of controls. Furthermore, CD39 downregulation and the number of CD68 cells were strongly associated with poor pregnancy outcomes (P < 0.01 and P < 0.05, respectively), but other histological parameters (CD3, C4d, and fibrin) did not show this association. Our study suggests that CD39 downregulation is a useful marker of CIUE and is associated with poor pregnancy outcomes in patients with CIUE.

Entities:  

Keywords:  Abortion; C4d; CD3; CD39; CD68; Chronic intervillositis of unknown etiology; Fetal growth restriction

Mesh:

Substances:

Year:  2019        PMID: 31218404     DOI: 10.1007/s00428-019-02598-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  5 in total

1.  Myeloid cell thrombus and fetal vascular malperfusion in placentas with transient abnormal myelopoiesis.

Authors:  Kayo Tomimori; Yuki Kodama; Hiroyuki Tanaka; Atushi Yamashita; Toshihiro Gi; Yujiro Asada; Koutarou Doi; Shinji Katsuragi; Yuichiro Sato
Journal:  Virchows Arch       Date:  2022-02-24       Impact factor: 4.064

Review 2.  Chronic Inflammatory Placental Disorders Associated With Recurrent Adverse Pregnancy Outcome.

Authors:  Emily F Cornish; Thomas McDonnell; David J Williams
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

3.  The Missing Role of Prenatal Diagnosis of Chronic Histiocytic Intervillositis in the Management of Growth Restricted Fetuses.

Authors:  Sedigheh Hantoushzadeh; Maasoumeh Saleh; Sepehr Aghajanian; Behnaz Nouri
Journal:  Front Med (Lausanne)       Date:  2022-02-02

4.  C4d deposition and CD39 downregulation in the placental infection by SARS-CoV-2.

Authors:  Yoshiya Shimao; Aya Yamauchi; Teruo Ohtsuka; Kiminari Terao; Yuki Kodama; Naoshi Yamada; Yujiro Asada; Yuichiro Sato
Journal:  Pathol Int       Date:  2022-02-14       Impact factor: 2.534

5.  The percentage of CD39+ monocytes is higher in pregnant COVID-19+ patients than in nonpregnant COVID-19+ patients.

Authors:  A Cérbulo-Vázquez; M García-Espinosa; J C Briones-Garduño; L Arriaga-Pizano; E Ferat-Osorio; B Zavala-Barrios; G L Cabrera-Rivera; P Miranda-Cruz; M T García de la Rosa; J L Prieto-Chávez; V Rivero-Arredondo; R L Madera-Sandoval; A Cruz-Cruz; E Salazar-Rios; M E Salazar-Rios; D Serrano-Molina; R C De Lira-Barraza; A H Villanueva-Compean; A Esquivel-Pineda; R Ramirez-Montes de Oca; F Caldiño-Soto; L A Ramírez-García; G Flores-Padilla; O Moreno-Álvarez; G M L Guerrero-Avendaño; C López-Macías
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.